Particularly, 30% of the patients were found to have JAK2 mutations, and 10% of the patients were found to have NRAS or CSF3R mutations, suggesting that kinase signaling pathways are possibly associated with the progression of AEL. This evidence concerns the gene JAK2 and acute erythroid leukemia.